+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticonvulsants Market by Drug Class, Indication, Route Of Administration, Distribution Channel, Formulation - Global Forecast to 2030- Product Image
Anticonvulsants Market by Drug Class, Indication, Route Of Administration, Distribution Channel, Formulation - Global Forecast to 2030- Product Image
Sale

Anticonvulsants Market by Drug Class, Indication, Route Of Administration, Distribution Channel, Formulation - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305569
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anticonvulsants market is navigating a complex transformation driven by shifting treatment paradigms, emerging digital health solutions, and evolving regulatory demands. Executive leaders in pharma, biotech, and healthcare must align strategy to capitalize on major advances and address marketplace pressures impacting neurological and psychiatric care.

Market Snapshot: Anticonvulsants Market

The Anticonvulsants Market grew from USD 13.07 billion in 2024 to USD 14.23 billion in 2025. It is expected to continue growing at a CAGR of 8.74%, reaching USD 21.61 billion by 2030. Strong global demand spans epilepsy, bipolar disorder, migraine prophylaxis, and neuropathic pain, propelled by advances in neurobiology, targeted therapies, and drug delivery innovation. Major industry players are focused on expanding portfolios, adapting to payer requirements, and leveraging data-driven real world evidence to sustain growth and market access. Regional variations dictate competitive approaches and access models, while partnership structures are becoming central in accelerating both development and commercialization initiatives.

Scope & Segmentation

  • Drug Classes: Benzodiazepines (such as clobazam, clonazepam, diazepam), Carbonic Anhydrase Inhibitors (acetazolamide, methazolamide), GABA Analogues (gabapentin, pregabalin, vigabatrin), Sodium Channel Blockers (carbamazepine, lamotrigine, phenytoin), SV2A Modulators (brivaracetam, levetiracetam).
  • Indications: Bipolar disorder (type I, type II), epilepsy subtypes (absence seizures, focal seizures, generalized seizures, myoclonic seizures, status epilepticus), migraine prophylaxis, neuropathic pain (diabetic neuropathy, postherpetic neuralgia).
  • Routes of Administration: Injectable, oral, rectal, transdermal.
  • Distribution Channels: Drug stores, hospital pharmacies, online and retail pharmacies.
  • Formulations: Capsules, injections, solutions, suspensions, tablets.
  • Geographies: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (covering both mature and emerging markets), Asia-Pacific (including China, India, Japan, Australia, Southeast Asia).
  • Company Landscape: Key companies include Pfizer Inc., Eisai Co., Ltd., Novartis AG, AbbVie Inc., Johnson & Johnson, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., and GlaxoSmithKline plc.

Key Takeaways for Decision-Makers

  • Strategic portfolio diversification and API sourcing are becoming critical as manufacturers respond to both regulatory and trade headwinds.
  • The convergence of pharmacogenomics and digital monitoring platforms is raising the standard for personalized care and adherence, sharpening competitive differentiation.
  • Segment performance shows robust demand for benzodiazepines and GABA analogues, while off-label utilization for migraine and neuropathic pain is expanding addressable markets.
  • Payer pressure is intensifying, requiring robust demonstration of value via real world evidence and pharmacoeconomic modeling in negotiation and reimbursement processes.
  • Collaborations between biotechs and established pharma players continue to accelerate the pace of new therapy commercialization, especially for refractory conditions and novel mechanisms.
  • Global market access demands regionally tailored strategies as healthcare policy, reimbursement norms, and access to generics vary considerably across geographies.

Tariff Impact on the Anticonvulsants Market

The introduction of United States tariffs in 2025 has driven up input costs by affecting the supply of key active ingredients and intermediates, impacting both branded and generic manufacturers. As a direct result, companies have realigned supply contracts, diversified supplier sourcing, and increased reliance on domestic API production or vertical integration—actions exerting direct influence on production timelines and margins. Payers and health systems have responded with tighter formulary control and stricter evidence requirements for price adjustments, prompting manufacturers to emphasize effective cost management and dynamic pricing strategies. These measures are shaping ongoing access, market continuity, and risk mitigation efforts across industry stakeholders.

Methodology & Data Sources

This analysis leverages comprehensive primary and secondary research, including interviews with industry experts, clinicians, and payers, as well as reviews of peer-reviewed literature, regulatory filings, and corporate data. Market databases, trade publications, and patent registries informed supply chain and competitive trends. Rigorous data triangulation, statistical and thematic analysis, and internal peer review ensure reliability and actionable insight throughout the research process.

Why This Report Matters

  • Enables strategic planning with granular intelligence on therapy, indication, and geographic drivers shaping opportunities and challenges.
  • Supports informed investment and partnership decisions by clarifying evolving clinical, regulatory, and trade factors affecting growth.
  • Empowers teams to anticipate payer demands, optimize market access, and future-proof portfolios in a shifting landscape.

Conclusion

The anticonvulsants market is defined by innovation, regulatory adaptation, and new access pressures. Responsive strategies and data-driven decision-making will help industry leaders leverage emerging opportunities and anticipate challenges as the sector evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anticonvulsants Market, by Drug Class
8.1. Introduction
8.2. Benzodiazepines
8.2.1. Clobazam
8.2.2. Clonazepam
8.2.3. Diazepam
8.3. Carbonic Anhydrase Inhibitors
8.3.1. Acetazolamide
8.3.2. Methazolamide
8.4. Gaba Analogues
8.4.1. Gabapentin
8.4.2. Pregabalin
8.4.3. Vigabatrin
8.5. Sodium Channel Blockers
8.5.1. Carbamazepine
8.5.2. Lamotrigine
8.5.3. Phenytoin
8.6. Sv2A Modulators
8.6.1. Brivaracetam
8.6.2. Levetiracetam
9. Anticonvulsants Market, by Indication
9.1. Introduction
9.2. Bipolar Disorder
9.2.1. Type I
9.2.2. Type II
9.3. Epilepsy
9.3.1. Absence Seizures
9.3.2. Focal Seizures
9.3.3. Generalized Seizures
9.3.4. Myoclonic Seizures
9.3.5. Status Epilepticus
9.4. Migraine Prophylaxis
9.5. Neuropathic Pain
9.5.1. Diabetic Neuropathy
9.5.2. Postherpetic Neuralgia
10. Anticonvulsants Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Rectal
10.5. Transdermal
11. Anticonvulsants Market, by Distribution Channel
11.1. Introduction
11.2. Drug Stores
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Anticonvulsants Market, by Formulation
12.1. Introduction
12.2. Capsule
12.3. Injection
12.4. Solution
12.5. Suspension
12.6. Tablet
13. Americas Anticonvulsants Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anticonvulsants Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anticonvulsants Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Eisai Co., Ltd.
16.3.3. Novartis AG
16.3.4. AbbVie Inc.
16.3.5. Johnson & Johnson
16.3.6. Sanofi S.A.
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Viatris Inc.
16.3.9. GlaxoSmithKline plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTICONVULSANTS MARKET MULTI-CURRENCY
FIGURE 2. ANTICONVULSANTS MARKET MULTI-LANGUAGE
FIGURE 3. ANTICONVULSANTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. CANADA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 93. CANADA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. CANADA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 95. CANADA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 96. CANADA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 97. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. CANADA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 99. CANADA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 100. CANADA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 101. CANADA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. CANADA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 114. MEXICO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 172. GERMANY ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 185. FRANCE ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. FRANCE ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 187. FRANCE ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 192. FRANCE ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 193. FRANCE ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. FRANCE ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. FRANCE ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. ITALY ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 211. ITALY ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. ITALY ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 213. ITALY ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 214. ITALY ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 215. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. ITALY ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 217. ITALY ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 218. ITALY ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 219. ITALY ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. ITALY ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. ITALY ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. SPAIN ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 224. SPAIN ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. SPAIN ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 226. SPAIN ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 227. SPAIN ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 228. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. SPAIN ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 230. SPAIN ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 231. SPAIN ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 232. SPAIN ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SPAIN ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SPAIN ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 274. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. DENMARK ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 276. DENMARK ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. DENMARK ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 278. DENMARK ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. DENMARK ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 282. DENMARK ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 283. DENMARK ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 284. DENMARK ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. DENMARK ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. DENMARK ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 300. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 301. QATAR ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 302. QATAR ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. QATAR ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 304. QATAR ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 305. QATAR ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 306. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 307. QATAR ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 308. QATAR ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 309. QATAR ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 310. QATAR ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. QATAR ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. QATAR ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. FINLAND ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 315. FINLAND ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. FINLAND ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 317. FINLAND ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 318. FINLAND ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 319. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. FINLAND ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 321. FINLAND ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 322. FINLAND ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 323. FINLAND ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. FINLAND ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. FINLAND ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. SWEDEN ANTICONVULSANTS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anticonvulsants market report include:
  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • AbbVie Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.23 Billion
Forecasted Market Value ( USD ) by 2030 $ 21.61 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Anticonvulsants Market Report 2025 - Product Image

Anticonvulsants Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report by Disease, Drug Class (Anticonvulsants, CNS Stimulants), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Trigeminal Neuralgia Therapeutics Market by Therapy Type, Product Type, Mechanism Of Action, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Trigeminal Neuralgia Therapeutics Market by Therapy Type, Product Type, Mechanism Of Action, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030 - Product Image

Neuropathic Pain Drug Market by Product Type, Route of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Krabbe Disease Treatment - Global Strategic Business Report - Product Image

Krabbe Disease Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Anticonvulsants Market

Anticonvulsants are a class of drugs used to treat seizures and other neurological disorders. They work by reducing the abnormal electrical activity in the brain that causes seizures. Anticonvulsants are used to treat a variety of conditions, including epilepsy, bipolar disorder, and neuropathic pain. They are also used to prevent seizures in people with certain types of brain injuries. Anticonvulsants are part of the larger class of Central Nervous System (CNS) drugs, which also includes antidepressants, antipsychotics, and anxiolytics. The anticonvulsant market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Other companies include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.